Quanterix (QTRX) AI Stock Analysis

• Market Cap: $208.63M
• Dividend Yield: N/A
• Average Volume (3M): 756.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: -2.74%
• EPS Growth: -96.96%
• Country: US
• Employees: 471
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): -0.77
• Shares Outstanding: 46,465,916
• 10 Day Avg. Volume: 747,719
• 30 Day Avg. Volume: 756,240
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: 0.26
• Enterprise Value/Gross Profit: 0.47
• Enterprise Value/Ebitda: -0.39
• 1Y Price Target: $6.20
• Price Target Upside: 42.53% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5

• Rating: 48 Neutral
• Price Target: $5.00 ▲(14.94% Upside)

Quanterix's overall stock score reflects significant financial challenges, including declining revenues and negative cash flow, which are the most impactful factors. While strategic initiatives and corporate events offer potential for future growth, current financial and technical indicators suggest caution.

Positive Factors

Insider Activity

Recent insider purchases could suggest these individuals believe the stock is undervalued.

Strategic Developments

The Akoya acquisition, progress in diagnostics and upcoming launch of the Simoa One instrument should drive stronger performance over time.

Negative Factors

Market Challenges

Quanterix's results were impacted by increasing headwinds in biopharma and continued NIH funding uncertainty.

Product Sales

Consumables sales declined 15%, which is concerning as they are expected to be resilient in challenging environments.

Revenue Performance

Total revenue of $24.5M fell short of already lowered expectations, with significant declines in both academic and pharma sectors.

Quanterix Business Overview & Revenue Model

Company Description

Quanterix Corporation (QTRX) is a biotechnology company that focuses on advancing the field of precision medicine through its innovative technology platform. The company specializes in ultra-sensitive biomarker detection and analysis, enabling researchers and clinicians to better understand and diagnose diseases. Quanterix operates primarily in the life sciences sector, offering products and services that include their Simoa (Single Molecule Array) technology, which allows for the measurement of low-abundance biomarkers in various applications such as oncology, neurology, and cardiology.

How the Company Makes Money

Quanterix generates revenue through the sale of its proprietary Simoa technology systems, consumables, and related services to academic, pharmaceutical, and biotechnology companies. The company has multiple key revenue streams, including instrument sales, which provide upfront revenue, and ongoing sales of consumables that are required for the operation of their systems. Additionally, Quanterix earns revenue from service contracts and collaborations with pharmaceutical companies for specialized biomarker analysis and clinical trials. Strategic partnerships with major research institutions and pharmaceutical companies further contribute to its earnings through collaborative research agreements and co-development projects that leverage Quanterix's technology for drug development and biomarker discovery.

Quanterix Financial Statement Overview

Summary

Quanterix shows revenue growth but struggles with profitability, as indicated by negative net income and EBIT margins. The balance sheet is strong with low debt, but negative cash flows highlight operational challenges.

Income Statement

The company has shown revenue growth over several years, but profitability is a concern with consistently negative net income and EBIT margins. Gross profit margin is relatively stable, but high operating losses impact overall performance.

Balance Sheet

The balance sheet is solid with a healthy equity base and low debt levels, as indicated by a low debt-to-equity ratio. However, the company is not yet generating positive returns on equity due to ongoing net losses.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow has shown some improvement but remains negative, indicating the company is not yet self-sustaining.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	125.38M	137.42M	122.37M	105.52M	110.56M	86.38M
Gross Profit	69.64M	81.12M	70.65M	46.24M	61.73M	48.18M
EBITDA	-84.62M	-44.26M	-15.63M	-91.88M	-53.24M	-27.27M
Net Income	-70.50M	-38.53M	-32.33M	-96.70M	-57.69M	-31.53M
Balance Sheet
Total Assets	375.61M	406.53M	425.01M	434.20M	501.53M	271.05M
Cash, Cash Equivalents and Short-Term Investments	261.17M	289.12M	321.32M	338.74M	396.46M	181.58M
Total Debt	35.53M	37.37M	41.46M	44.10M	21.89M	30.80M
Total Liabilities	83.15M	76.50M	78.08M	75.26M	60.58M	64.92M
Stockholders Equity	292.46M	330.04M	346.93M	358.94M	440.95M	206.13M
Cash Flow
Free Cash Flow	-32.89M	-38.53M	-22.69M	-60.00M	-61.52M	-27.30M
Operating Cash Flow	-29.59M	-35.16M	-18.90M	-48.27M	-47.91M	-23.36M
Investing Cash Flow	114.60M	-82.27M	-148.40M	-11.21M	-6.34M	-626.00K
Financing Cash Flow	-151.00K	456.00K	2.69M	2.31M	270.80M	96.24M

Quanterix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTRX, the sentiment is Negative. The current price of 4.35 is below the 20-day moving average (MA) of 4.78, below the 50-day MA of 5.54, and below the 200-day MA of 7.35, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 33.30 is Neutral, neither overbought nor oversold. The STOCH value of 7.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QTRX.

Quanterix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELMD	70 Outperform	$206.48M	28.26	17.18%	―	16.97%	48.56%
Sector *	51 Neutral	$7.90B	-0.33	-41.69%	2.23%	23.45%	-1.99%
CERS	49 Neutral	$243.46M	―	-35.98%	―	13.25%	23.81%
QTRX	48 Neutral	$208.63M	―	-22.27%	―	-2.74%	-96.96%
ANIK	46 Neutral	$131.93M	―	-22.91%	―	-25.85%	18.18%
LUNG	44 Neutral	$70.49M	―	-66.88%	―	18.24%	4.81%
RCEL	42 Neutral	$115.53M	―	-935.73%	―	38.32%	-1.31%

Quanterix Corporate Events

Quanterix Adopts New Bylaws Amid Financial Challenges

On August 5, 2025, Quanterix‘s Board of Directors adopted new bylaws to implement a majority voting standard for uncontested director elections. The company also announced financial results for the second quarter of 2025, reporting a revenue decrease of 29% compared to the previous year and a net loss of $30 million. Despite these challenges, Quanterix highlighted significant growth in its Alzheimer’s Diagnostics revenues and strategic actions aimed at long-term growth, including the completion of its acquisition of Akoya Biosciences. The company is focused on achieving cash flow breakeven in 2026 and expects to exit 2025 with approximately $120 million in cash and cash equivalents.

Quanterix Announces Cooperation Agreement with Kent Lake

On August 4, 2025, Quanterix Corporation announced a cooperation agreement with Kent Lake Partners LP to appoint a new independent director by December 1, 2025, and to seek shareholder approval to declassify its board. This agreement includes amending bylaws for a majority voting standard in uncontested elections and Kent Lake’s withdrawal of previous director nominations and proposals. The collaboration aims to enhance governance and focus on the company’s strategic goals, potentially benefiting stakeholders and positioning Quanterix for continued success.

Quanterix Announces Cost-Cutting Measures Post-Acquisition

On July 18, 2025, Quanterix Corporation announced a plan to reduce operating costs and preserve cash through a series of terminations as part of its integration strategy following the acquisition of Akoya Biosciences, Inc. This move is expected to result in annualized cash savings of approximately $18 million, primarily through headcount reductions to be completed by the third quarter of 2025. However, the company anticipates incurring expenses of around $2.5 million for severance. The actual financial impact may vary based on several assumptions, and Quanterix has acknowledged potential risks and uncertainties that could affect the expected outcomes.

Quanterix Announces Executive Termination for Cost Savings

On July 14, 2025, Quanterix Corporation announced a plan to terminate certain executives of its newly acquired subsidiary, Akoya Biosciences, Inc., as part of an integration strategy to achieve cost savings and operational efficiencies. The move is expected to result in annual cash savings of approximately $2.8 million, although it will incur expenses of around $3.3 million in 2025 for severance payments. The company acknowledges that actual results may vary from these estimates and additional charges could arise.

Quanterix Completes Acquisition of Akoya Biosciences

On July 8, 2025, Quanterix Corporation completed its acquisition of Akoya Biosciences, creating a comprehensive platform for measuring biomarkers across blood and tissue. This acquisition is expected to expand Quanterix’s market from $1 billion to $5 billion and accelerate its path to profitability by 2026. As part of the merger, Akoya designated Scott Mendel and Myla Lai-Goldman, MD, to join Quanterix’s Board of Directors, replacing Martin D. Madaus, PhD, and Sarah Hlavinka, who resigned on July 7, 2025. The merger positions Quanterix as a scaled leader in early disease detection for neurology, oncology, and immunology markets.

Quanterix Revises Deadlines for Stockholder Proposals

On June 26, 2025, Quanterix Corporation’s board announced that the 2025 Annual Meeting of Stockholders will be held virtually on September 23, 2025. Due to the meeting’s date being more than 30 days from the previous year’s meeting, deadlines for stockholder proposals and nominations have been revised, with new deadlines set for July 11 and July 25, 2025, to comply with SEC rules and the company’s bylaws.